🇺🇸 Montanide ISA 51 VG in United States
7 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 7
Most-reported reactions
- Atrial Fibrillation — 2 reports (28.57%)
- Pneumonia — 2 reports (28.57%)
- Pneumonitis — 2 reports (28.57%)
- Sepsis — 1 report (14.29%)
Other Oncology approved in United States
Frequently asked questions
Is Montanide ISA 51 VG approved in United States?
Montanide ISA 51 VG does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Montanide ISA 51 VG in United States?
National Cancer Institute (NCI) is the originator. The local marketing authorisation holder may differ — check the official source linked above.